Nichole Tucker | Authors

November 22, 2022

Results from the phase 3 KEYNOTE-859 study show extended overall and progression-free survival in patients with HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal adenocarcinoma treated with pembrolizumab and chemotherapy.

November 22, 2022

In an interview with Targeted Oncology, Michael T. Tees, MD, discussed the donor-derived CAR T-cell product, ALLO-501A, and research supporting the agent.

November 21, 2022

Based on positive findings from the phase 2 pivotal EPCORE NHL-1, the FDA will conduct a speedy review of the biologics license application for subcutaneous epcoritamab for the treatment of patients with relapsed/refractory large B-cell lymphoma after 2 or more lines of systemic therapy an granted it priority review.

November 20, 2022

In an interview with Targeted Oncology, Megan R. Haymart, MD, provided a recap of a symposium at the American Thyroid 2022 Annual Meeting and discussed disparities in thyroid cancer care, as well as potential solutions

November 18, 2022

Real-world evidence from Florida Cancer Specialists & Research Institute shows that trilaciclib may reduce the chance of patients with extensive-stage small cell lung cancer experiencing chemotherapy-induced myelosuppression events.

November 17, 2022

Initial results from the phase 3 spotlight study show that the study met its primary and key secondary end point of progression-free and overall survival.